Immunotherapy, in the setting of advanced prostate cancer (PCa), may alter the lethal condition of advanced PCa into a chronic disease with significantly longer overall survival (OS), says an expert.
The future of poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors in the treatment of metastatic castration-resistant prostate cancer (mCRPC) is promising in light of encouraging results from recent clinical studies.
Since the approval of immune checkpoint inhibitors (ICIs) as standard of care in the second-line setting for metastatic urothelial carcinoma, new approaches on how clinicians manage this condition are emerging.
Studies have demonstrated that robot-assisted radical cystectomy (RARC) is as effective and has a cost advantage compared with open cystectomy for the management of urologic cancers.
Recent research has revealed various potential biomarkers for metastatic castration-resistant prostate cancer (mCRPC), but several challenges remain in fully utilizing them in clinical practice.